In a study already mentioned above, 73% of 48 MM patients were found to have positive ctDNA for BRAF and NRAS mutations by ddPCR prior to treatment with anti-PD-1 +/− anti-CTLA-4 or BRAF/MEKi [42]. This evidence concerns the gene CTLA4 and Miyoshi myopathy.